Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Iron chelation therapy elicits innate immune control of metastatic ovarian cancer

ABSTRACT: Iron chelation therapy elicits innate immune control of metastatic ovarian cancer

PROVIDER: PRJNA1031179 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26484730_1.fastq.gz	Fastqsanger.gz
	SRR26484730_2.fastq.gz	Fastqsanger.gz
	SRR26484731_1.fastq.gz	Fastqsanger.gz
	SRR26484731_2.fastq.gz	Fastqsanger.gz
	SRR26484732_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 17

Similar Datasets

Iron chelation therapy elicits innate immune control of metastatic ovarian cancer

Project description:Iron accumulation in cancer cells contributes to malignant progression and chemoresistance. While disrupting this process can influence various hallmarks of cancer, the immunomodulatory effects of chelating iron in tumors remain undefined. Here, we report that treatment with deferiprone, an FDA-approved iron chelator, elicits innate immune responses that control metastatic ovarian cancer. Deferiprone reprogrammed ovarian cancer cells towards an immunostimulatory state characterized by enhanced production of type I interferon (IFN) and surface overexpression of molecules that activate natural killer (NK) cells. Mechanistically, this reprogramming was driven by innate sensing of mitochondrial DNA in the cytosol and concomitant activation of nuclear DNA damage responses evoked upon iron chelation. Deferiprone administration synergized with chemotherapy and prolonged the survival of mice bearing metastatic ovarian cancer by bolstering intratumoral NK cell infiltration and type I IFN responses. Iron chelation may represent an alternative immunotherapeutic approach for malignancies that are normally refractory to T cell-centric modalities.

2024-06-26 | GSE246051 | GEO

Heme Deficient vs Wild Type in Low Iron

Project description:Heme Deficient or Wild Type (normal heme) for 6 hrs with iron chelation by BPS. Keywords: Cell Type Comparison

2005-10-18 | GSE3470 | GEO

Treatment of a human lymphoblastoid cell line with the iron chelator deferoxamine

Project description:We treated lymphoblast cells with the iron chelator deferoxamine (DFO) for 60 hours to determine if iron chelation would affect the levels of intron lariats.

2022-03-23 | GSE199077 | GEO

Iron Chelators Treatment on DMS-53 Human Lung Cancer Cell

Project description:The molecular role of iron in gene expression remains poorly characterized. Moreover, the alterations in global gene expression after iron chelation remains unclear and are important to assess for understanding the molecular pathology of iron-depletion and the biological effects of iron chelators. We assessed the effect on whole genome gene expression of two iron chelators (desferrioxamine and Dp44mT). These studies are important for understanding the molecular and cellular effects of iron-depletion.

2011-12-31 | GSE26920 | GEO

Heme Deficient vs Wild Type in Low Iron

Project description:Heme Deficient or Wild Type (normal heme) for 6 hrs with iron chelation by BPS. Single Experiment with Probe Reversal 1. GSM78518 (Cy3) vs GSM78519 (Cy5) 2. GSM78520 (Cy3) vs GSM78521 (Cy5)

2010-06-30 | E-GEOD-3470 | biostudies-arrayexpress

RNA-seq of Highly Metastatic and Lowly Metastatic 4T1 Single Clones Treated with Iron Chelator Deferasirox (DFX)

Project description:Using bulk RNA-seq, the transcriptional profile of two cell lines with high or low metastatic properties derived from single clones of the murine 4T1 cell line treated or untreated with iron chelator DFX was analyzed in order to determine the mechanism underlying the inhibition preference of DFX for highly metastatic 4T1 cells.

2022-11-16 | GSE218133 | GEO

Iron controls the development of airway hyperreactivity by regulating ILC2 metabolism and effector function

Project description:Group 2 innate lymphoid cells (ILC2s) rapidly induce a type 2 inflammation in the lungs in response to allergens. Here, we focused on the role of iron – a critical nutritional trace element – on ILC2 function and asthma pathogenesis. In the lungs, transferrin receptor 1 (TfR1) is rapidly upregulated and functional during ILC2 activation, while blocking transferrin uptake reduces ILC2 expansion and activation. Iron deprivation reprograms ILC2 metabolism, inducing a HIF-1a-driven upregulation of glycolysis and inhibition of oxidative mitochondrial activity. Consequently, in vivo iron chelation or induction of hypoferremia notably reduces the development of airway hyperreactivity in experimental models of ILC2-driven allergic asthma. Human circulating ILC2s rapidly induce TfR1 during activation, while iron deprivation reduces effector functions. Finally, we found a negative relation between circulating ILC2 TfR1 expression and airway function in cohorts of patients with asthma. Collectively, our studies define cellular iron as a critical regulator of ILC2 function.

2024-05-21 | GSE262210 | GEO

CITE-seq of LSK cells from aged mice after long-term iron chelator regimen

Project description:We found that iron chelation restored functional defects in aged HSC, including engraftment potential and platelet bias. To gain molecular insights into iron-dependent mechanism for sustaining HSC identity during aging, we performed Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) with lineage (Lin)− Sca-1+ cKit+ (LSK) cells isolated from aged mice after long-term regimens with iron chelator Deferoxamine or vehicle control.

2024-05-02 | GSE232022 | GEO

Iron Chelators Treatment on MCF-7 Human Breast Cancer Cell

Project description:Iron-deficiency affects 500 million people, yet the molecular role of iron in gene expression remains poorly characterized. Moreover, the alterations in global gene expression after iron chelation remains unclear and are important to assess for understanding the molecular pathology of iron-deficiency and the biological effects of iron chelators. We assessed the effect on whole genome gene expression of two iron chelators (desferrioxamine and 2-hydroxy-1-napthylaldehyde isonicotinoyl hydrazone) that have markedly different permeability properties. Sixteen genes were significantly regulated by both chelators, while a further 50 genes were regulated by either ligand. Most of the genes identified in this study have not been previously described to be iron-regulated and are important for understanding the molecular and cellular effects of iron-deficiency.

2010-02-28 | GSE17832 | GEO

Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3

Project description:Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3

| PRJNA545250 | ENA